Evaluation of the toxicity of 5-Aryl-2-Aminoimidazole-based biofilm inhibitors against eukaryotic cell lines, bone cells and the nematode caenorhabditis elegans

Molecules

Volumn 19, Issue 10, 2014, Pages 16707-16723

  Steenackers, Hans ^a   Dubey, Akanksha ^a   Robijns, Stijn ^a   Ermolat'ev, Denis ^b   Delattin, Nicolas ^a   Dovgan, Barbara ^c   Girandon, Lenart ^e   Frohlich, Mirjam ^c,f   Brucker, Katrijn De ^a   Cammue, Bruno P A ^a,g   Thevissen, Karin ^a   Balzarini, Jan ^d   Van Der Eycken, Erik V ^b   Vanderleyden, Jozef ^a  

^a Centre of Microbial and Plant Genetics ^*  (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Educell Ltd   (Slovenia)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e CELL TRY Ltd   (Slovenia)

^f JO EF STEFAN INSTITUTE   (Slovenia)

^g DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

5 Aryl 2 Aminoimidazole; Biofilm inhibitor; Bone cells; Caenorhabditis elegans; Toxicity; Tumor cell lines

Indexed keywords

2-AMINOIMIDAZOLE; CYTOSTATIC AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL; BIOFILM; CAENORHABDITIS ELEGANS; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EUKARYOTIC CELL; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; HUMAN; NEOPLASMS; OSTEOBLAST; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; BIOFILMS; CAENORHABDITIS ELEGANS; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOSTATIC AGENTS; EUKARYOTIC CELLS; HUMANS; IMIDAZOLES; NEOPLASMS; OSTEOBLASTS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84911947294     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191016707     Document Type: Article

References (39)

1. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: A common cause of persistent infections. Science 1999, 284, 1318-1322.
2. Donlan, R.M.; Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002, 15, 167-193.
3. Hall-Stoodley, L.; Hu, F.Z.; Gieseke, A.; Nistico, L.; Nguyen, D.; Hayes, J.; Forbes, M.; Greenberg, D.P.; Dice, B.; Burrows, A.; et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006, 296, 202-211.
4. Bjarnsholt, T.; Jensen, P.O.; Fiandaca, M.J.; Pedersen, J.; Hansen, C.R.; Andersen, C.B.; Pressler, T.; Givskov, M.; Hoiby, N. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 2009, 44, 547-558.
5. Davies, D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2003, 2, 114-122.
6. Hall-Stoodley, L.; Stoodley, P. Evolving concepts in biofilm infections. Cell Microbiol. 2009, 11, 1034-1043.
7. Hoiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 2010, 35, 322-332.
8. Jensen, P.O.; Givskov, M.; Bjarnsholt, T.; Moser, C. The immune system vs. Pseudomonas aeruginosa biofilms. FEMS Immunol. Med. Microbiol. 2010, 59, 292-305.
9. Burmolle, M.; Thomsen, T.R.; Fazli, M.; Dige, I.; Christensen, L.; Homoe, P.; Tvede, M.; Nyvad, B.; Tolker-Nielsen, T.; Givskov, M.; et al. Biofilms in chronic infections-A matter of opportunity- monospecies biofilms in multispecies infections. FEMS Immunol. Med. Microbiol. 2010, 59, 324-336.
10. Hassett, D.J.; Korfhagen, T.R.; Irvin, R.T.; Schurr, M.J.; Sauer, K.; Lau, G.W.; Sutton, M.D.; Yu, H.; Hoiby, N. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: Insights into pathogenic processes and treatment strategies. Expert Opin. Ther. Targets 2010, 14, 117-130.
11. Bjarnsholt, T.; Tolker-Nielsen, T.; Hoiby, N.; Givskov, M. Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control. Expert Rev. Mol. Med. 2010, 12, e11.
12. Landini, P.; Antoniani, D.; Burgess, J.G.; Nijland, R. Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal. Appl. Microbiol. Biotechnol. 2010, 86, 813-823.
13. Steenackers, H.; Ermolat'ev, D.S.; Savaliya, B.; de Weerdt, A.; de Coster, D.; van der Eycken, E.; de Vos, D.; Vanderleyden, J.; de Keersmaecker, S.C. Structure Activity Relationship of 4(5)-Phenyl-2-Amino-1H-imidazoles, N1-Substituted 2-Aminoimidazoles and Imidazo[1,2- a]pyrimidinium Salts as Inhibitors of the Biofilm Formation by Salmonella Typhimurium and Pseudomonas aeruginosa. J. Med. Chem. 2010, 54, 472-482.
14. Steenackers, H.P.; Ermolat'ev, D.S.; Savaliya, B.; Weerdt, A.D.; Coster, D.D.; Shah, A.; van der Eycken, E.V.; de Vos, D.E.; Vanderleyden, J.; de Keersmaecker, S.C. Structure-Activity relationship of 2-hydroxy-2-Aryl-2,3-dihydro-imidazo[1,2-A]pyrimidinium salts and 2N-substituted 4(5)-Aryl-2-Amino-1H-imidazoles as inhibitors of biofilm formation by Salmonella Typhimurium and Pseudomonas aeruginosa. Bioorg. Med. Chem. 2011, 19, 3462-3473.
15. Ermolat'ev, D.S.; Bariwal, J.B.; Steenackers, H.P.; de Keersmaecker, S.C.; van der Eycken, E.V. Concise and diversity-oriented route toward polysubstituted 2-Aminoimidazole alkaloids and their analogues. Angew. Chem. Int. Ed. Engl. 2010, 49, 9465-9468.
16. Steenackers, H.; Ermolat'ev, D.; Trang, T.; Savalia, B.; de Weerdt, A.; Shah, A.; Vanderleyden, J.; van der Eycken, E. Microwave-Assisted One-Pot Synthesis and Anti-Biofilm Activity of 2-Amino-1H-imidazole/Triazole Conjugates. Org. Biomol. Chem. 2014, 12, 3671-3678
17. Stowe, S.D.; Richards, J.J.; Tucker, A.T.; Thompson, R.; Melander, C.; Cavanagh, J. Anti-biofilm compounds derived from marine sponges. Mar. Drugs 2011, 9, 2010-2035.
18. Sullivan, J.D.; Giles, R.L. 2-Aminoimidazoles from Leucetta sponges: Synthesis and Biology of an Important Pharmacophore. Curr. Bioact. Compd. 2009, 5, 39-78.
19. Lavelle, F.; Zerial, A.; Fizames, C.; Rabault, B.; Curaudeau, A. Antitumor activity and mechanism of action of the marine compound girodazole. Investig. New Drugs 1991, 9, 233-244.
20. Tsukamoto, S.; Yamashita, K.; Tane, K.; Kizu, R.; Ohta, T.; Matsunaga, S.; Fusetani, N.; Kawahara, H.; Yokosawa, H. Girolline, an antitumor compound isolated from a sponge, induces G2/M cell cycle arrest and accumulation of polyubiquitinated p53. Biol. Pharm. Bull. 2004, 27, 699-701.
21. Bickmeyer, U. Bromoageliferin and dibromoageliferin, secondary metabolites from the marine sponge Agelas conifera, inhibit voltage-operated, but not store-operated calcium entry in PC12 cells. Toxicon 2005, 45, 627-632.
22. Liotta, L.A. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986, 46, 1-7.
23. Gross, H.; Kehraus, S.; Konig, G.M.; Woerheide, G.; Wright, A.D. New and biologically active imidazole alkaloids from two sponges of the genus Leucetta. J. Nat. Prod. 2002, 65, 1190-1193.
24. Hassan, W.; Edrada, R.; Ebel, R.; Wray, V.; Berg, A.; van Soest, R.; Wiryowidagdo, S.; Proksch, P. New imidazole alkaloids from the Indonesian sponge Leucetta chagosensis. J. Nat. Prod. 2004, 67, 817-822.
25. Tsukamoto, S.; Kawabata, T.; Kato, H.; Ohta, T.; Rotinsulu, H.; Mangindaan, R.E.; van Soest, R.W.; Ukai, K.; Kobayashi, H.; Namikoshi, M. Naamidines H and I, cytotoxic imidazole alkaloids from the Indonesian marine sponge Leucetta chagosensis. J. Nat. Prod. 2007, 70, 1658-1660.
26. Copp, B.R.; Fairchild, C.R.; Cornell, L.; Casazza, A.M.; Robinson, S.; Ireland, C.M. Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor. J. Med. Chem. 1998, 41, 3909-3911.
27. James, R.D.; Jones, D.A.; Aalbersberg, W.; Ireland, C.M. Naamidine A intensifies the phosphotransferase activity of extracellular signal-regulated kinases causing A-431 cells to arrest in G1. Mol. Cancer Res. 2003, 2, 747-751.
28. Aberle, N.; Catimel, J.; Nice, E.C.; Watson, K.G. Synthesis and biological evaluation of analogues of the anti-tumor alkaloid naamidine A. Bioorg. Med. Chem. Lett. 2007, 17, 3741-3744.
29. Huigens, R.W., 3rd; Ma, L.; Gambino, C.; Moeller, P.D.; Basso, A.; Cavanagh, J.; Wozniak, D.J.; Melander, C. Control of bacterial biofilms with marine alkaloid derivatives. Mol. Biosyst. 2008, 4, 614-621.
30. Stowe, S.D.; Tucker, A.T.; Thompson, R.; Piper, A.; Richards, J.J.; Rogers, S.A.; Mathies, L.D.; Melander, C.; Cavanagh, J. Evaluation of the toxicity of 2-Aminoimidazole antibiofilm agents using both cellular and model organism systems. Drug Chem. Toxicol. 2012, 35, 310-315.
31. Glowacka, I.E.; Balzarini, J.; Wroblewski, A.E. Design, synthesis, antiviral, and cytotoxic evaluation of novel phosphonylated 1,2,3-triazoles as acyclic nucleotide analogues. Nucleosides Nucleotides Nucleic Acids 2012, 31, 293-318.
32. Balzarini, J.; Thomas, J.; Liekens, S.; Noppen, S.; Dehaen, W.; Romagnoli, R. 2-Aminothiophene- 3-carboxylic acid ester derivatives as novel highly selective cytostatic agents. Investig. New Drugs 2014, 32, 200-210.
33. Ekwall, B. Screening of toxic compounds in mammalian cell cultures. Ann. N. Y. Acad. Sci. 1983, 407, 64-77.
34. Ekwall, B.; Silano, A.; Paganuzzi-stammati, A.; Zucco, F. Toxicity Tests with Mammalian Cell Cultures. In Short-term Toxicity Tests for Non-genotoxic Effects; Bourdeau, P., Ed., John Wiley &Sons Ltd: Hoboken, NJ, USA, 1990; pp. 75-99.
35. Leung, M.C.; Williams, P.L.; Benedetto, A.; Au, C.; Helmcke, K.J.; Aschner, M.; Meyer, J.N. Caenorhabditis elegans: An emerging model in biomedical and environmental toxicology. Toxicol. Sci. 2008, 106, 5-28.
36. Antoshechkin, I.; Sternberg, P.W. The versatile worm: Genetic and genomic resources for Caenorhabditis elegans research. Nat. Rev. Genet. 2007, 8, 518-532.
37. Kaletta, T.; Hengartner, M.O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov. 2006, 5, 387-398.
38. Glatt, V.; Kwong, F.N.; Park, K.; Parry, N.; Griffin, D.; Vrahas, M.; Evans, C.H.; Harris, M. Ability of recombinant human bone morphogenetic protein 2 to enhance bone healing in the presence of tobramycin: evaluation in a rat segmental defect model. J. Orthop. Trauma 2009, 23, 693-701.
39. O'Callaghan, D.; Vergunst, A. Non-mammalian animal models to study infectious disease: Worms or fly fishing? Curr. Opin. Microbiol. 2010, 13, 79-85